Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) traded down 8.3% during mid-day trading on Thursday . The company traded as low as $15.52 and last traded at $15.76, with a volume of 285,949 shares changing hands. The stock had previously closed at $17.19.

A number of equities research analysts have issued reports on the company. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Eiger BioPharmaceuticals in a research report on Thursday, August 11th. Zacks Investment Research downgraded Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, June 13th. Piper Jaffray Cos. reissued a “buy” rating and set a $33.00 price target (up previously from $30.00) on shares of Eiger BioPharmaceuticals in a research report on Thursday, April 21st. Oppenheimer Holdings Inc. assumed coverage on Eiger BioPharmaceuticals in a research report on Tuesday, July 5th. They set an “outperform” rating and a $34.00 price target for the company. Finally, Jefferies Group reissued a “buy” rating on shares of Eiger BioPharmaceuticals in a research report on Monday, May 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $34.50.

The company has a 50-day moving average price of $19.11 and a 200 day moving average price of $18.56. The company’s market cap is $111.53 million.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its earnings results on Wednesday, August 10th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.17) by $0.70. On average, equities analysts expect that Eiger BioPharmaceuticals Inc. will post ($8.15) EPS for the current year.

In related news, insider James P. Shaffer bought 1,250 shares of Eiger BioPharmaceuticals stock in a transaction that occurred on Monday, June 13th. The stock was acquired at an average price of $22.17 per share, for a total transaction of $27,712.50. Following the completion of the purchase, the insider now owns 1,975 shares in the company, valued at $43,785.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James H. Welch bought 2,500 shares of Eiger BioPharmaceuticals stock in a transaction that occurred on Wednesday, June 22nd. The stock was bought at an average price of $19.80 per share, with a total value of $49,500.00. Following the purchase, the chief financial officer now owns 2,000 shares of the company’s stock, valued at approximately $39,600. The disclosure for this purchase can be found here.

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.